The REDEFINE 1/2 ladder: 0.25 mg (5u), 0.5 mg (10u), 1.0 mg (20u), 1.7 mg (34u), four weeks per step
The main outcome was a composite measure capturing the occurrence of end-stage renal disease or a 40-percent decline in the glomerular filtration rate
We have not seen another GLP-1 clinic tie treatment access to SMS consent
Mering C, Krause R, Snel B, Cornell M, Oliver SG, Fields S, and Bork P
Liraglutide was finally approved in 2010 for the treatment of patients with type 2 diabetes unable to regulate their blood sugar with other insulin medications (Gilbert, Rosenthal, Jan 2024)